Pharvaris NV(PHVS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:25 PM ET (Korea 10/31 05:25)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.05 | Insider Own | 51.9% | Shs Outstand | 70.2M | Perf Week | 6.75% |
| Market Cap | 2.34B | Forward P/E | - | EPS next Y | 3.17% | Insider Trans | -2.42% | Shs Float | 33.6M | Perf Month | 8.13% |
| Enterprise Value | 1.98B | PEG | - | EPS next Q | -0.81 | Inst Own | 47.92% | Short Float | 7.34% | Perf Quarter | 3.97% |
| Income | -0.20B | P/S | - | EPS this Y | 5.99% | Inst Trans | 10.3% | Short Ratio | 3.15 | Perf Half Y | 13.89% |
| Sales | 0.00B | P/B | 6.84 | EPS next 5Y | 33.6% | ROA | -64.08% | Short Interest | 2.47M | Perf YTD | 20.83% |
| Book/sh | 4.9 | P/C | 6.44 | EPS past 3/5Y | -11.96% -21.68% | ROE | -71.14% | 52W High | -22.47% ($43.25) | Perf Year | 50.76% |
| Cash/sh | 5.21 | P/FCF | - | Sales past 3/5Y | - | ROIC | -57.86% | 52W Low | 59.51% ($21.02) | Perf 3Y | 97.7% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 9.42% | Gross Margin | - | Volatility(W/M) | 2.78% 4.16% | Perf 5Y | 92.37% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.94 | EPS Q/Q | 13.3% | Profit Margin | - | RSI (14) | 59.57 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.94 | Sales Q/Q | - | SMA20 | 8.05% ($31.03) | Beta | -2.49 | Target Price | $57.51 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/12 | SMA50 | -0.4% ($33.66) | Rel Volume | 1.89 | Prev Close | $33.58 |
| Employees | 129 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -8.7% - | SMA200 | 8.18% ($30.99) | Avg Volume(3M) | 0.78M | Price | $33.53 |
| IPO | 2021/2/5 | Option/Short | Yes/Yes | Trades | 7850 | Volume | 1,482,027 | Change | -0.15% |
🧬 This is a clinical-stage biotech company developing treatments for hereditary angioedema. It develops oral therapies that target specific signaling pathways that trigger swelling and has candidates spanning both the treatment and prevention of attacks. This differentiated biotech is entering a rare disease area with significant unmet need by offering an oral treatment that improves convenience compared with existing injectables.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
Traded more than usual. That is 189% of its average volume.
PHVS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +6.0% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +92.4%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 47.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #85 of 597 in the industry
Based on market cap of $2B.
FAQ
What kind of company is PHVS?
PHVS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PHVS?
The market cap of PHVS is approximately $2.3B, ranking 1,938 within its sector.
What is the 52-week high and low for PHVS?
PHVS has recorded a 52-week high of $43.25 and a low of $21.02.
